Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3092 Neoplasms 2436 Carcinoma, Non-Small-Cell Lung 1863 Prostatic Neoplasms 1617 Colorectal Neoplasms 1422 Lung Neoplasms 1292 Multiple Myeloma 927 Neoplasm Metastasis 919 Leukemia, Myeloid, Acute 874 Pancreatic Neoplasms 847 Ovarian Neoplasms 799 Melanoma 783 Carcinoma, Hepatocellular 736 Stomach Neoplasms 639 Brain Neoplasms 635 Recurrence 633 Squamous Cell Carcinoma of Head and Neck 630 Head and Neck Neoplasms 609 Glioblastoma 566 Lymphoma 539 Uterine Cervical Neoplasms 537 Triple Negative Breast Neoplasms 504 Precursor Cell Lymphoblastic Leukemia-Lymphoma 499 Carcinoma, Renal Cell 497 Hematologic Neoplasms 462 Urinary Bladder Neoplasms 459 Endometrial Neoplasms 459 Colonic Neoplasms 441 Lymphoma, Non-Hodgkin 435 Sarcoma 434

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × 1 year × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡